QP Pharmachem asked to stop manufacturing after samples found to be of non-standard quality: Govt

Published On 2023-08-12 08:00 GMT   |   Update On 2023-10-26 11:03 GMT
Advertisement

New Delhi: A Punjab-based drugmaker was asked to stop all manufacturing activities after samples collected from its premises, following an alert by the WHO, were found to be "not of standard quality", the Lok Sabha was informed on Friday. Minister of State for Health Bharati Pravin Pawar, in a written reply in the Lower House of Parliament, said the World Health Organization (WHO) issued a medical product alert for a batch of India-made Guaifenesin syrup in the Marshall Islands and the Federated States of Micronesia.

Subsequent to the reports, the Central Drugs Standard Control Organisation (CDSCO) in coordination with State Drugs Authority, Punjab, conducted a joint investigation at M/s QP Pharmachem Ltd in Punjab.
"Drug samples drawn from the manufacturing premises under the provisions of Drugs and Cosmetics Act, 1940 for test and analysis were declared as 'not of standard quality'," the minister said.
"Further, the State Licensing Authority has directed the firm to stop all manufacturing activities with immediate effect," Pawar said.
The WHO on April 25 issued a product alert over a batch of substandard (contaminated) Guaifenesin syrup, warning that it is unsafe for use, especially in children, and may result in serious injury or death.
In response to a question on whether the Centres for Disease Control and Prevention of the United States of America has expressed concern that a drug-resistant bacteria strain allegedly linked to eye drops from India could gain a foothold in US healthcare settings, Pawar said, "No such report has been received"

Read also: Manufacturing licences of QP Pharmachem, 2 others suspended

Medical Dialogues team had reported that the Drug Controller General of India (DCGI) had notified all drug manufacturers' associations and exporters not to submit the same batch of cough syrup to more than one laboratory at a time, as this practice is highly objectionable and not acceptable from a regulatory standpoint.

Read also: Do not submit same batch no. of cough syrup to two different laboratories: DCGI tells Manufacturers, Exporters

Tags:    
Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News